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1  | INTRODUC TION
The mitochondrion is a complex intracellular organelle. Its high 
abundance in cells gives a strong indicator as to its importance in 
cellular function. Their number and shape differ according to the cell 
type.1 Research so far has revealed that mitochondria have multiple 
important roles, including ATP production,2 Ca2+ homeostasis,3,4 and 
reactive oxygen species (ROS) production.5,6
The mitochondrion has a unique evolutionary background, 
where it is thought that they originated from α‐proteobacteria.7 
Evidence of this resides in the presence of mitochondrial DNA. 
Unlike genomic DNA, mitochondrial DNA is circular in form and 
therefore has similarities to bacterial DNA in structure. While 
mitochondrial DNA does code for some proteins important for 
mitochondrial function, the majority of mitochondrial structural 
proteins are encoded by the cell nucleus, where the proteins are im‐
ported and sorted into the mitochondria.8 In addition to structure, 
mitochondrial DNA differs from genomic DNA in the copy num‐
ber, where often mitochondria can contain many more copies of 
DNA. Mitochondrial DNA is inherited predominantly through the 
maternal line,9 and therefore, any mitochondrial DNA mutations 
will pass from the mother to her children.
Due to the diverse and crucial role of the mitochondrion within 
the cell, the mitochondrial integrity is important to cell survival. 
There are a large number of diseases where mitochondria, either 
directly or indirectly, become dysfunctional. This review aims to de‐
scribe the processes for mitochondrial function, the mitochondrial 
pathways that are initiated during mitochondrial dysfunction, and 
how this relates to neurodegenerative diseases.
2  | FUNDAMENTAL S OF MITOCHONDRIAL 
BIOLOGY
2.1 | Mitochondrion structure
Healthy mitochondria are required for sufficient ATP production 
and cellular function. The mitochondrion, consisting of a jelly‐like 
matrix, is a double‐membrane organelle found in multiple copies 
within each cell. They are encompassed by the inner mitochondrial 
membrane (IMM), a highly folded membrane. Beyond the IMM is 
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Summary
The mitochondrion is a unique organelle with a diverse range of functions. 
Mitochondrial dysfunction is a key pathological process in several neurodegenera‐
tive diseases. Mitochondria are mostly important for energy production; however, 
they also have roles in Ca2+ homeostasis, ROS production, and apoptosis. There are 
two major systems in place, which regulate mitochondrial integrity, mitochondrial 
dynamics, and mitophagy. These two processes remove damaged mitochondria from 
cells and protect the functional mitochondrial population. These quality control sys‐
tems often become dysfunctional during neurodegenerative diseases, such as 
Parkinson's and Alzheimer's disease, causing mitochondrial dysfunction and severe 
neurological symptoms.
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the intermembrane space (IMS), which is between the IMM and the 
outer mitochondrial membrane (OMM).10
The matrix is a key area for respiration, as within this space, both 
the tricarboxylic acid (TCA) cycle and the breakdown of pyruvate 
into adenine triphosphate (ATP) take place. This process leads to 
the production of H+ ions which are necessary for the final step of 
mitochondrial respiration. Two important protein produced within 
the matrix are FADH2 and NADH. These molecules are important 
substrates for mitochondrial respiration. NADH is used as substrate 
to reduce ubiquinone to ubiquinol in complex II of the electron 
transport chain (ETC).11 NADH transfers electrons to complex I, the 
NADH Q reductase, which causes NADH to be reduced into NAD+ 
and releases H+ ions into the matrix. Embedded within the IMM are 
several more proteins that make up the ETC Complex II, III, IV, and 
V are also found in the IMM, and together they form the ETC One 
important component of the ETC is cytochrome C, which plays an 
important role in both ATP production and cell apoptosis.12 This will 
be discussed in further detail later on. The OMM is the second mito‐
chondrial membrane, separating the IMS from the cytosol. There are 
multiple proteins found on the OMM, with a diverse range of func‐
tions, such as receptors for autophagy molecules, and membrane 
proteins involved in mitochondrial division and fusion.
Both the IMM and OMM contain mitochondrial translocase pro‐
teins, Tim, and Tom proteins, respectively. These proteins have an im‐
portant role in the import of mitochondrial structure proteins. Both 
the Tim and Tom proteins consist of multiple subunits, which form 
a complex spanning the mitochondrial membrane. The major sub‐
units which form the pore in the IMM and OMM, Tim23 and Tom40, 
respectively, allow passage through the double membrane into the 
matrix. In the IMM, five other different subunits have been identi‐
fied: Tim17, Tim23, Tim44, Tim11 (these four subunits have been 
found to be closely associated with each other), and Tim22, which is 
important for cell survival. In the OMM, the Tom complex consists 
of nine subunits: Tom5, Tom6, Tom7, Tom20, Tom22, Tom37, Tom 
70, Tom72, and Tom40. The Tom complex draws proteins into the 
central pore, Tom40, via the receptor subunits, Tom20, 22, 37, 70 
and 72, and through into IMS (Figure 1). The Tom and Tim machinery 
is crucial for mitochondrial structure as mitochondria import the vast 
majority of their structure proteins.13
2.2 | Mitochondrial membrane potential
The mitochondrial membrane potential (sometimes denoted as Δψm) 
is generated by protons pumped into the inner membrane space (IMS) 
of the mitochondrion. This occurs in the final step during oxidative 
phosphorylation, which also results in ATP production. Electrons are 
passed along the ETC, initiated by the transference from substrates 
such as NADH, from the matrix to the ETC14 Electron flows laterally 
along the IMM then reaches the terminal ETC complex, F0F1‐ATP 
synthase enzyme, or otherwise known as complex V of the ETC, 
situated on the IMM15,16 (Figure 2).
The generation of ATP from ADP is catalyzed by the F0F1 ATP 
synthase enzyme. This reaction requires the movement of protons 
through the IMM, from the IMS into the matrix. The F0F1 ATP syn‐
thase enzyme consists of two complexes, the F0 and the F1. These 
proteins act as motors, which are able to twist and change confor‐
mation. They are connected by central stalks, which allow them to 
affect each other's movement and activity. The F1 component is 
found protruding outside the IMM, into the matrix of the mitochon‐
drion. In contrast, the F0 component is found embedded in the IMM. 
Studies have shown that the F0 component is vital for the movement 
of protons across the mitochondrial membrane and for the produc‐
tion of the mitochondrial membrane potential. The F1 component, 
however, is important for the generation of ATP, as well as the 
F I G U R E  1   The Tim and Tom 
complexes. The key pore proteins are 
Tom40 and Tim23, for the OMM and the 
IMM, respectively. In the Tom complex, 
smaller subunits Tom5, Tom6, and Tom7 
are within the OMM. Larger subunits 
Tom20, Tom22, Tom37, Tom70, and 
Tom71 are receptor proteins, which bind 
to proteins and guide them into the IMS. 
The main Tim complex is comprised of 
additional subunits Tim11, Tim17, and 
Tim44. Proteins enter to the matrix via the 
Tom and Tim complexes. Proteins such 
as alpha‐synuclein bind to the receptor 
Tom20, which then guides them into the 
Tom40 pore (blue line)
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hydrolysis of ATP into ADP. Depending on the enzymatic reaction, 
whether it might be ATP production or hydrolysis, the rotation of 
the F1 motor is changed which alters the spin of the unit.
17 When 
the H+ ions cross from the IMS into the matrix, ADP is converted 
to ATP, which is used as a form of energy by the cell. This generates 
an electrochemical gradient across the inner membrane (Figure 2). 
Measuring this electrochemical gradient has been proposed to be a 
relative indicator of the generation of ATP.16 In addition to ATP pro‐
duction, mitochondrial membrane potential is also directly involved 
in import of important ions and mitochondrial structural proteins. 
The majority of mitochondrial proteins are imported into the mito‐
chondrion as precursor proteins. These precursor proteins contain 
either mitochondrial targeting sequences, which direct the protein 
to the correct apartment, or they contain N‐terminal presequences 
that allow them to pass through the OMM and IMM, after which 
they are cleaved. The electrostatic charge across the mitochondrial 
membrane, with a negative intracellular charge, allows the import 
of positively charged precursor proteins and cations such as Ca2+ or 
Fe2+. The precursor of cytochrome b2, for example, which is found in 
the IMM, is one such protein that relies on the mitochondrial mem‐
brane potential for its translocation into the mitochondria. It was 
found that cytochrome b2 contained a positively charged N‐terminal 
sequence, which drove the movement of the protein toward the neg‐
atively charged IMM, first into the matrix and then to be sorted into 
the IMS. When the mitochondrial membrane potential is abolished, 
the import of cytochrome b2 into the mitochondrion is inhibited, 
suggesting that the translocation of cytochrome b2 into the matrix 
is dependent on the mitochondria membrane potential generated 
across the IMM.18‐20
So far, there are two proteins which are thought to be involved in 
the maintenance of mitochondrial membrane potential; these being 
ATPase inhibitory factor 1 (IF1) and adenine nucleotide translocase 
(ANT). The first modulator, IF1, is a nuclear‐encoded protein. It works 
as an endogenous inhibitor of ATP synthase, by binding directly to the 
F0F1 ATPase.
21 ANT is an ADP/ATP carrier where it catalyzes the con‐
version of ADP to ATP in the IMM and is closely involved in oxidative 
phosphorylation. In stressful conditions where mitochondrial func‐
tion is impaired, the ADP/ATP carrier attempts to maintain the mito‐
chondrial potential, by prioritizing the membrane potential over ATP 
production, and causes the carrier to reverse the enzymatic reaction, 
so that ATP is converted into ADP, exporting it into the cytoplasm.22
2.3 | Mitochondrial permeability transition pore
The mitochondrion contains certain voltage‐dependent channels 
within the mitochondrial membrane. This pore, when open, allows 
certain elements to flow from the mitochondrion, thus altering and 
controlling the permeability of the mitochondrial membrane. This 
can therefore allow the transport of proteins, which otherwise 
would be impermeable to the IMM. When the permeability pore is 
open, small proteins of up to 1.5 kDa, which otherwise are imperme‐
able, can pass through the IMM.23
The transition pores can be either in a reversible open or closed 
state. The probability of the high conductive pore opening can be 
F I G U R E  2   Structure of the ETC The ETC is comprised of five main complexes which span the IMM. In complex I, NADH, which is 
produced in the TCA cycle, is reduced to NAD+ and H+ ions. The H+	ions	are	pumped	out	into	the	IMS	and	the	electrons	(e−)	are	passed	
onto complex II, which catalyzes the reduction in FADH2 to FAD. Complex II is also a part of the TCA cycle, and FAD can also be oxidized to 
form FADH2, which in turn reduces succinate to form fumarate in the TCA cycle. Electrons are passed through the coenzyme Q, reducing 
ubiquinone into ubiquinol, and then into complex III. Cytochrome C allows the flow of electrons from complex III to complex IV. At complex 
IV, H+ ions in the matrix react with O2 molecules to form H2O. In addition H
+ ions are also pumped out into the IMS. At complex V, also 
known as ATP synthase, H+ ion, which have accumulated in the IMS, then pass down the concentration gradient back into the matrix. This H+ 
ion flow causes the F0F1 ATPase to rotate, which catalyzes the phosphorylation of ADP, generating ATP molecules into the matrix
828  |     COWAN et Al.
modulated by both the mitochondrial membrane potential and the 
pH gradient. In fact, it had been suggested that part of the ATP syn‐
thase, the machinery which generates the mitochondrial membrane 
potential, forms part of the mitochondrial permeability transition 
pore (MPTP).24 The permeability of the pore is intrinsically related 
to changes in Ca2+ ion homeostasis, which is a strong and essential 
trigger for MPTP opening. In this regard, the mitochondrial calcium 
uniporter (MCU), a channel which allows calcium transport into the 
matrix, has a direct effect on the MPTP.25
The MPTP has caught the interest of scientists for many years. 
However, despite this, there has been little conclusive evidence of 
its structure. There have many studies with the aim to determine 
the proteins involved in the MPTP and over the years different pro‐
teins have been proposed, including adenine nucleotide translocase 
(ANT) and the voltage‐dependent anion channel (VDAC). ANT was 
proposed many years ago, by the scientists Hunter and Haworth, 
as it had been shown to be sensitive to certain ligands which can 
modulate MPTP opening.26 However, firm confirmation of its direct 
involvement in MPTP function has not yet been made, so it is unclear 
how important the protein is in the MPTP. VDAC, a protein found 
in the OMM, is an ion channel pore that changes it open or closed 
state in the response to changes in the mitochondrial membrane 
potential. VDAC is thought to play an important role in membrane 
permeability, but it had also been found to be equally important 
in apoptosis. The proteins Bax/Bak interact with VDAC and cause 
the pore to open more readily, which would allow cytochrome C to 
be exported into the cytosol.27 However, the protein cyclophilin D 
(CypD) is generally accepted as a protein found in the MPTP.28 The 
importance of CypD was discovered mainly through the effect of the 
drug cyclosporine A (CsA), which had an inhibiting effect on CypD.25 
The addition of CsA was found to desensitize the MPTP to Ca2+ ions, 
preventing MPTP opening. The precise function of CypD within the 
MPTP is not clear however. It has been suggested that CypD may 
regulate the opening of the MPTP; the mechanisms by which this 
happens however are not well known either.
2.4 | Cytochrome C
Mitochondrial metabolism is a key mitochondria process and is 
heavily regulated through redox reactions. One of the key proteins 
involved in these redox reactions is cytochrome C. Cytochrome C 
is normally situated within the IMS, where it has an important role 
in mitochondrial respiration. The size restriction, of 1.5 kDa, pre‐
vents larger proteins, such as cytochrome C from passing through 
the MPTP. The release of cytochrome C occurs when the OMM is 
disrupted, which releases cytochrome C out of the IMS into the cy‐
toplasm.29,30 Cytochrome C has a diverse range of cellular functions. 
In addition to apoptosis, it has been found to be heavily involved in 
the mitochondrial ETC, where it acts as an electron carrier between 
complex III and complex IV. Complex III within the ETC consists of a 
bc1 complex. The bc1 complex transfers an electron to complex IV. 
Cytochrome C augments this transfer to complex IV, by transferring 
the electron onto cytochrome oxidase in complex IV. After four such 
electron transfers, oxygen is then converted to water and two elec‐
trons are released from the matrix into the IMS.31
In addition, cytochrome C is able to reduce the effects of ROS, 
by acting as a ROS scavenger and removing electrons from oxygen 
species. ROS includes molecules such as superoxide (O⋅−
2
) and hy‐
droxyl radical (·OH), both of which are classed as free radicals, and 
hydrogen peroxide (H2O2). These ROS molecules contain oxygen, 
which have free radicals and are highly reactive and toxic, even to 
DNA. These ROS species are formed from the oxygen molecules 
produced from the electron transport chain, especially in complex I 
and III.32 Complex III, a multisubunit complex also named the cyto‐
chrome bc1 complex, is found within the IMM, is able to generate 
ROS via the Qo site within complex III, which then causes ROS to 
be released into the IMS.33 Although complex I and complex III are 
the major sources of ROS production in the mitochondrion, com‐
plex II has also been found to produce ROS in certain conditions.34 
Complex II catalyzes the conversion of succinate to fumarate, but 
when there are low levels of succinate, or if complex I or III are in‐
hibited, complex II can produce superoxide molecules or hydrogen 
peroxide in the matrix. Due to its importance in ROS production 
and apoptosis, cytochrome C is closely regulated. Cytochrome C 
can be modulated by ATP and phosphorylation. ATP can bind to 
directly to cytochrome C, which inhibits its activity.35 There have 
been several phosphorylation sites identified so far, including 
Tyr97, Try48, and Thr28, when these sites are phosphorylated, it 
reduces the electron flow across the ETC and prevents ROS pro‐
duction and apoptosis.36
3  | MITOCHONDRION‐REL ATED 
CY TOTOXICIT Y
3.1 | Mitochondrial‐dependent apoptotic death
One of the key roles of the mitochondrion is the induction of apop‐
tosis. Under pathological conditions, cell death signaling molecules 
are released from the mitochondrion into the cytoplasm, triggering 
apoptosis of the cell. This occurs through the permeabilization of 
the outer mitochondrial membrane, which enables these molecules 
to leave the IMS into the cytoplasm.37 Mitochondrion‐depend‐
ent apoptosis is regulated by the Bcl‐2 family proteins. The Bcl‐2 
family proteins are comprised of three groups of proteins: Bax/
Bak proteins, Bcl‐2‐like proteins, and Bcl‐2 homology 3 (BH3)‐only 
proteins.38
Bax/Bak proteins are directly involved in apoptosis, where 
they form a channel within the OMM, causing OMM permeabili‐
zation.39 Once this happens, mitochondrion‐dependent apoptotic 
death is determined. In addition to the Bax/Bak protein group, 
the BH3‐only protein group was found to be indirectly involved 
in mitochondrial permeabilization. The BH3‐only proteins, such as 
truncated Bid (tBid), have been identified as such factors. tBid is 
a BH3 interacting domain death agonist and can stimulate Bax/
Bak activation and translocation to the OMM. tBid, once activated 
by the key pro‐apoptotic protein caspase‐8, activates Bak/Bax 
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which causes permeabilization of the OMM.38,40 tBid, and other 
BH3‐only proteins, such as Bim, PUMA and Noxa, can also bind to 
Bcl‐2 proteins and inhibit their activity.38 Bcl‐2 proteins are able to 
bind to Bax/Bak, reducing OMM permeabilization caused by the 
latters. When tBid, Bim, PUMA, or Noxa binds to Bcl‐2 proteins, it 
allows Bax/Bak to become activated and increases OMM perme‐
abilization (Figure 3).
A key signaling molecule during apoptosis is the caspase protein, 
which is released into the cytoplasm. Caspases are cysteine aspar‐
tate proteases. Its activation can be induced by several different 
stimuli, such as DNA damage, tumorigenesis, and oxidative stress.41 
After OMM permeabilization, certain proteins are released from the 
mitochondrion into cytosol, which then in turn activate caspases. 
These include the proteins Smac, Omi, and cytochrome C, which can 
all be found in the IMS. Smac and Omi both help to initiate caspase 
activity by binding and preventing the actions of a caspase inhibitor 
XIAP.42
While more commonly known as an important ETC protein, 
cytochrome C is a particularly important IMS protein for caspase 
activation. Cytochrome C binds to the caspase adaptor molecule 
Apaf‐1, altering its conformation. Apaf‐1 recruits caspase‐9, to‐
gether forming a large collective complex, known as the apopto‐
some. This recruitment occurs through the exposure of the caspase 
activation and recruitment domains (CARD) in Apaf‐1.43 Through 
caspase‐9 dimerization, the apoptosome is activated, which then 
cleaves and activates, caspase‐3 and caspase‐7, causing severe cell 
death42 (Figure 3).
3.2 | Mitochondrial‐derived neuroinflammation
In the same way, that cells exhibit an inflammatory response to 
invading pathogens, mitochondrial damaged‐associated molecular 
pattern (DAMPs) is a process by which a damaged mitochondrion 
releases signaling molecules into the cytoplasm, in response to 
stress. It has been suggested that this process may be involved in 
many diseases, including heart disease, sepsis,44 and neurodegen‐
eration. There is an intricate relationship between mitochondrial 
DAMPs, which are also known as alarmins, and neuroinflamma‐
tion. Mitochondria release signaling molecules which are recog‐
nized by PRRs (pattern recognition receptor), such as the toll‐like 
receptors (TLRs) or the NOD‐like receptors (NLR). NLR3, one such 
member of the NLR family, is normally found in the endoplasmic 
reticulum. When the agonist of NLR3 is bound, it causes the re‐
ceptor to translocate to the mitochondrion to oligomerize and this 
recruits the protein ASC, apoptosis‐associated speck‐like protein 
with a caspase activation and recruitment domain (CARD). This 
complex then binds to procaspase‐1 which altogether forms the 
NLRP3 inflammasome.45,46 There have been several molecules 
that were specifically identified as DAMP molecules; these include 
ATP, cytochrome C, mtDNA,47 and mitochondrial transcription 
factor A (TFAM).48 These DAMP molecules are recognized by the 
PRRs, which initiates the cascade of pro‐inflammatory pathways, 
as well as initiating astrogliosis and activating microglia.
Mitochondrial dysfunction, which results in the generation 
of DAMP molecules response, leads to the recruitment of key 
F I G U R E  3   Mitochondrion‐dependent apoptosis. When the mitochondrion is damaged, BH3‐only proteins activate Bak and/or Bax, 
causing permeabilization of the OMM (red line representing the permeabilization of the OMM). Bcl‐2 proteins including Bcl‐2, Bcl‐x, and 
MCL inhibit Bak/Bax activity. Once the OMM is permeabilized, several IMS‐localized proteins, such as cytochrome C, transport out of the 
mitochondrial in the cytosol (dotted line represents the movement of cytochrome C). Cytochrome C activates Apaf‐1, which in turn binds to 
caspase‐9, to form a complex, the apoptosome. This complex then activates caspase‐3 and caspase‐7, and leads to apoptosis. In addition to 
cytochrome C, the IMS‐localized protein Smac/Diablo enters the cytosol and inhibits XIAP, which is a caspase‐3 and caspase‐7 inhibitor. This 
leads to higher levels of caspase‐3 and caspase‐7 in the cytosol
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pro‐inflammatory molecules such as interleukin‐1β (IL‐1β) and cyto‐
kines such as TNFα. These cytokines however can themselves affect 
mitochondrial function, with TNFα capable of impairing the func‐
tion of mitochondrial ETC components, reducing ATP production, 
increasing ROS production, and depolarization of the mitochondrial 
membrane potential.46 Increased ROS can then have further effects 
by initiating activation of the nuclear factor NFkB, a key regulator 
of cytokine production, DNA transcription and pro‐inflammatory 
signaling. The stimulation of neuroinflammation can therefore also 
have a detrimental effect on mitochondrial function itself, thus cre‐
ating a vicious cycle.
4  | QUALIT Y CONTROL IN THE 
MITOCHONDRION
4.1 | Mitochondrial dynamics
Mitochondria have the ability to bind to other mitochondria, as well 
as to divide into two different mitochondria. These processes are 
collectively known as mitochondrial dynamics. This process allows 
the mitochondria to change morphologically, and increase or de‐
crease the mitochondria number within the cell. The process is me‐
diated by a group of proteins, the dynamin family, which all contain 
a GTPase domain. In addition to sharing this GTPase domain, they 
also share other domains: a middle domain, a variable domain, and 
a GTPase effector domain. All members of the family are able to 
bind to membranes, which occurs through activation of the variable 
domain.49
Mitochondrial fusion is the process by which two mitochondria 
fuse together to form one mitochondrion. This occurs by the binding 
of membrane‐bound proteins on the outer membranes of the mi‐
tochondria. The fusion of the inner mitochondrial membrane often 
then follows to form one mitochondrion, with the newly combined 
mitochondrion containing the contents of both mitochondria, such 
as the matrix and nutrients. This allows mitochondria to reduce any 
potential cell‐damaging molecules that may be in a segregated mi‐
tochondrion, ensuring mitochondrial survival and normal function. 
The process of mitochondrial fusion causes mitochondria to elon‐
gate, forming rod‐shaped mitochondria. The main proteins involved 
in mitochondrial fusion are Opa1, mitofusin 1 (Mfn1), and mitofusin 
2 (Mfn2). During fusion, Mfn1 and Mfn2, found on the OMM, bind 
to the same receptors on the neighboring mitochondria, which bring 
the two mitochondria together. The two OMMs fuse together creat‐
ing one continuous membrane.50
Mitochondrial fission, on the other hand, is regulated almost ex‐
clusively by the protein drp1 (dynamin‐related protein 1). The pre‐
cise mechanism of drp1 fission is not yet understood; however, it is 
known that drp1 binds to receptors on the OMM and oligomerizes to 
form a ring‐like structure around the mitochondria. The mitochon‐
drion is then divided into two daughter mitochondria, via GTPase 
hydrolysis. Drp1 proteins are recruited from the cytosol and bind to 
specific receptors on the OMM. The proteins MiD49, MiD51, Fis1, 
and Mff have recently all been identified as drp1 receptors on the 
OMM. MiD49 and MiD51, or mitochondrial dynamics proteins of 49 
and 51 kDa, are able to mediate drp1 fission by forming foci at the 
OMM and recruiting drp1 to the mitochondria. Knockdown of the 
MiD receptor prevented drp1 recruitment, leading to increased mi‐
tochondrial fusion. However, although they are able to recruit drp1, 
it was found that the MiD receptors dissociate from the OMM during 
GTPase hydrolysis. It was discovered that overexpressing the MiD 
receptors can prevent mitochondrial fission.51,52 Fis1 is a protein 
first found to interact with the drp1 orthologue, Dnm1, in yeast,53 
however, it was discovered that the interaction was not directly be‐
tween drp1 and Dnm1, but rather through two adaptor molecules, 
Mdv1 and Caf4.54,55 These adaptor molecules are not found in mam‐
mals, so the role of Fis1 in mammalian mitochondrial fission is not 
entirely clear. There has been a mixture of results, with some say‐
ing that Fis1 is not necessary for mitochondrial fission,56 and some 
studies showing Fis1 does interact and cause drp1‐dependent fis‐
sion.57,58 The receptor Mff on the other hand has been accepted the 
most as a mitochondrial fission receptor.56,57,59 A knockdown in Mff 
levels leads to a reduction in mitochondrial fission and an increase 
in the elongation of the mitochondria.58 Mitochondrial fission can 
help to control the mitochondrial quality by segregating damaged or 
unhealthy mitochondria away from the healthy mitochondria, and 
which would then be singled out for degradation via the mitophagy 
pathways.
4.2 | Mitophagy
Mitophagy is the process in which damaged mitochondria are de‐
graded by the autophagy system. This process is vital for remov‐
ing debris and aggregating proteins from the cells, thereby relieving 
the cells of potential cell‐damaging proteins. Damaged mitochondria 
are singled out and degraded, through the activities of the proteins 
PTEN‐induced kinase 1 (Pink1) and Parkin.60
Both Pink1 and Parkin are localized near healthy mitochondria in 
the cytosol. Pink1, a serine/threonine kinase, is encoded by nuclear 
DNA and has been shown to be involved upstream of Parkin, an E3 
ubiquitin ligase. The two protein work together to keep cells healthy 
by helping to clear any damaged mitochondria from the cell.61
In physiological conditions, Pink1, imported from the cytosol via 
mitochondrial translocases, is usually found within the IMM, where 
it is exported and proteolytically cleaved and degraded. Pink1 was 
discovered to have a mitochondrial targeting sequence (MTS) which 
directs the protein into the correct mitochondrial subcompartment. 
Pink1 is imported into the mitochondrion as a precursor, which is 
cleaved within the matrix by the protease MPPα/β.62 While it is 
thought that the N‐terminus of Pink1 has some involvement in mito‐
chondrial targeting, it has also been discovered that there are cleav‐
age sites situated within the N‐terminus which are cleaved by the 
MPP proteases. The import of Pink1 through the Tom complex is 
driven by the mitochondrial membrane potential, and once through, 
Pink1 then transports across the IMM via the Tim complexes. In its 
full form, Pink1 itself exists at 64 kDa. However, there have been 
reports of further cleavage of overexpressed Pink1, resulting in a 
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smaller 52 kDa form.63,64 This cleavage occurs when Pink1 binds to 
the protease PARL (presenilin‐associated rhomboid‐like), which is 
found within the IMM. Pink1 is then cleaved within its transmem‐
brane domain and is then transported to the cytosol where it is de‐
graded by cytosolic proteasome (Figure 4A).
When a mitochondrion is damaged, Pink1 levels at the OMM 
are increased. During mitochondrial damage, the mitochondrial 
membrane potential is altered and Pink1 is prevented from being 
able to enter through the OMM, causing Pink1 to accumulate on 
the OMM. Pink1 recruits Parkin, normally found in the cytosol, by 
phosphorylating ubiquitin found on certain protein on the OMM, 
which draws Parkin toward the mitochondrion. In addition to OMM 
surface proteins, Pink1 phosphorylates Parkin. This causes Parkin to 
become activated, and once activated Parkin initiates the process of 
degradation of the mitochondrion, where the mitochondrion is en‐
gulfed by the autophagosome and then consequently fuses with the 
lysosomes. Activated Parkin can then ubiquitinate other mitophagy 
receptors on the OMM. Both Parkin and Pink1 therefore contribute 
F I G U R E  4   Pink1 and Parkin in mitophagy in healthy and dysfunction mitochondria. A, In normal healthy mitochondria, Pink1 is 
predominantly expressed in the IMM. Pink1 is then translocated to the cytosol, where Pink1 is digested by the proteasome. Pink1 does not 
ubiquitinate OMM proteins and the cytosolic protein Parkin, and so Parkin is not activated. B, When mitochondria are extremely damaged, 
the Pink1‐Parkin pathway is activated. Pink1, instead of being degraded by the proteasome, is translocated to the OMM, which leads to 
its accumulation on the OMM. Pink1 phosphorylates both ubiquitin on the OMM and Parkin. The E3 ligase activity of Parkin is initiated, 
Parkin then ubiquitinates protein substrates, such as Miro, on the OMM, and also recruits the autophagosome to the mitochondrion for 
mitochondrial degradation
F I G U R E  5   An overview of mitochondrial dysfunction in PD (asyn), AD (Aβ), and HD (mHtt). Protein aggregates formed in these three 
neurodegenerative diseases negatively impact mitochondrial function. Although the exact mechanisms are not entirely understood, protein 
aggregates can lead to a disruption in the mitochondrial membrane potential, resulting in decreased ATP production. This disruption in 
membrane potential can lead to the permeabilization of the OMM, by opening the mitochondrial permeability transition pore (mPTP), 
leading to the release of pro‐apoptotic molecules such as cytochrome C. The impairment of the mitochondrial membrane potential can also 
prevent the import of mitochondrial structural proteins, such as the subunit cytochrome b2, which are normally produced in the nucleus and 
are translocated into the mitochondria through the Tom and Tim complexes. Protein aggregates can also disrupt mitochondrial dynamics 
(Drp1 and Opa1), leading to abnormal mitochondrial number and fragmentation. When the mitochondrion is damaged beyond repair, the 
mitophagy process is activated, which involves the recruitment of Pink1 to the OMM, which in turn recruits Parkin from the cytosol and 
activates it. The activation of Parkin then leads to the formation of the autophagosome, which degrades the damaged mitochondrion, 
removing it from the general mitochondrial population
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to the build‐up of phosphorylated ubiquitin and abundant accumu‐
lation of Pink1 on the OMM, which acts as an indicator to the cell 
that the mitochondrion is damaged and will need to be removed65 
(Figure 4B).
5  | MITOCHONDRIAL DYSFUNC TION IN 
NEURODEGENER ATION
Research into neurodegeneration so far has consistently reported 
changes in mitochondrial function, such as reduced ATP production 
and increased mitochondrial fragmentation. These mitochondrial 
dysfunctions can be seen in many different neurodegenerative dis‐
eases, suggesting that the underlying pathways behind mitochon‐
drial dysfunction are somewhat shared in all neurodegenerative 
diseases (Figure 5).
5.1 | Parkinson's disease
Parkinson's disease (PD), the second most common form of neurode‐
generative disease, is characterized by the accumulation of the pro‐
tein alpha‐synuclein, especially in the substantia nigra. This protein, 
found abundantly throughout the central nervous system, accumu‐
lates and forms Lewy bodies, a defining feature which is commonly 
found in the postmortem examination of PD patients.66 The relation‐
ship between alpha‐synuclein and mitochondria has been explored in 
several papers. It was shown that alpha‐synuclein can bind to and be 
imported directly into the mitochondria, which, when oligomerized, 
can have an adverse effect in PD.67 Normal alpha‐synuclein is thought 
to have some beneficial role in mitochondrial function. Alpha‐synu‐
clein, for example, is thought to bind to lipid membranes, such as 
the lipid membrane of the endoplasmic reticulum (ER), or more spe‐
cifically the mitochondrion‐associated ER membrane, through which 
the ER interacts with the mitochondrion.68 The study shows that mu‐
tated alpha‐synuclein reduces this interaction between the ER and 
the mitochondrion, suggesting that alpha‐synuclein has an important 
role in the communication between the two organelles.
Alpha‐synuclein was found to be directly localized with mito‐
chondria. Isolated mitochondria from PD patients were found to 
contain alpha‐synuclein.69 Alpha‐synuclein has been shown to have 
a strong affinity to mitochondria.67 This may be because alpha‐ 
synuclein has an affinity to cardiolipin, which is found through‐
out the IMM.70 Due to this relationship between alpha‐synuclein 
and mitochondria, research has been directed into understanding 
the changes in mitochondria in PD, and other synucleinopathies. 
The oligomerization and aggregation of alpha‐synuclein have been 
shown to cause deficits in the activities of complex I, which leads to 
a reduction in ATP production, depolarization of the IMM, and the 
release of pro‐apoptotic molecules into the cytosol.71,72
Studies into PD have also shown that alpha‐synuclein has a di‐
rect effect on mitochondria appearance, causing fragmentation of 
the mitochondria. Using a model of overexpressed alpha‐synuclein 
in dopaminergic neurons, some studies suggest that drp1 levels 
increase which causes increased fragmentation, cleavage of Opa1, 
leading to a reduction in mitochondrial fusion.73 In addition, inhibi‐
tion of drp1 can protect cells from cytotoxicity caused by mutated 
alpha‐synuclein.74 Studies have also suggested that alpha‐synuclein 
would readily bind to membrane and causes fragmentation of the 
membranes directly.75
One of the first key results to show that PD had a direct con‐
nection to mitochondria was the discovery of the mitophagy‐re‐
lated proteins, Pink1 and Parkin, thus suggesting that mitophagy in 
particular is very important in PD. They discovered that some PD 
patient had mutations in these proteins. Mutations in Pink176 and 
Parkin77 prevented normal function of mitophagy, as Pink1 was 
unable to phosphorylate OMM surface proteins, which prevented 
the clearance of damaged mitochondria. Pink1 has been found to 
interact with alpha‐synuclein itself in mitochondria and stimulate 
its clearance via mitophagy, reducing the toxicity caused by alpha‐ 
synuclein. This effect was abolished with a mutated form of Pink1, 
the point mutation G309D, which prevented Pink1 from interacting 
with alpha‐synuclein and being cleared from the mitochondria.78
5.2 | Huntington's disease
Huntington's disease (HD) is a devastating and fatal autosomal domi‐
nant inherited disease with no cure, causing motor dysfunction, 
memory deficits, and psychiatric symptoms.79 It is characterized by 
mutations in the Huntington's gene (Htt), which are the result of ab‐
normal expansion of the CAG repeats in the Htt gene, encoding an 
expanded polyglutamine (polyQ) stretch. Htt is then cleaved by pro‐
teolysis, which results in N‐terminus fragments, containing the ex‐
panded polyQ region. The Htt N‐terminus fragments become more 
prone to aggregation, and they accumulate together in the cytoplasm, 
locate especially in the striatum, as well as the frontal and temporal 
cortex. While the generation of cleaved mHtt is a common feature in 
HD, other forms of Htt are also thought to play a role in the progres‐
sion of HD. Soluble, monomeric forms of mHtt, found separate from 
mHtt aggregates, were found to be the toxic species and directly con‐
tribute to the neurodegeneration seen in HD pathology.80‐84
As with alpha‐synuclein and Aβ, Htt has been shown to bind 
directly to mitochondria. One studies showed that insoluble frag‐
mented Htt could bind directly to Tim23.85,86 Using Htt mutant pri‐
mary cells, they discovered Htt prevents the import of important 
proteins into the mitochondria, and this could be reversed through 
overexpressing Tim23 protein.
When the aggregate involved accumulates in neurons (alpha‐
synuclein in PD or Htt in HD), this can disrupt the function of the 
ETC Studies into HD patients have found reduced activity in com‐
plex II and complex III, as well as complex IV. A reduction in complex 
II in particular was discovered in the striatum of HD patients.87 In 
a transgenic mouse model of HD, they found that the structure of 
complex II was affected early in HD, and overexpressing complex 
II reduced the effects of mutated Htt on striatal neurons, relieving 
them from neuronal dysfunction. In other studies, this reduction in 
complex II was accompanied by a reduction in ATP production, as 
     |  833COWAN et Al.
insufficient oxidative phosphorylation results in a disruption of mi‐
tochondrial metabolism.86,88
The effect of mutant Htt on mitochondrial dynamics has also be‐
come a key focus in HD research. HD patients were found to have an 
imbalance in mitochondrial dynamics proteins, in postmortem tissue 
taken from the striatum of HD patients.89 They found decreased lev‐
els of fusion markers, such as Mfn1, Mfn2, and Opa1, and increased 
levels of fission markers drp1 and Fis1. This has subsequently been 
backed up with animal models and cells models. It was found that 
mutated Htt is able to interact with the mitochondrial fission GTPase 
protein drp1 and stimulate its activity directly. This caused mitochon‐
dria to fragment, leading to cellular dysregulation and death.90
5.3 | Alzheimer's disease
In Alzheimer's disease (AD), the most common form of neurodegen‐
erative dementia, the proteins amyloid beta, and tau form insoluble 
aggregates within the cell. AD pathology typically originates in the 
hippocampus and then develops into the neocortex, where damages 
in these regions can cause cognitive impairment such as memory de‐
cline and psychiatric disorder. The insoluble Aβ and tau aggregates 
accumulate over time, forming extracellular amyloid plaques, and 
intracellular neurofibrillary tangles, respectively, which disrupts nor‐
mal mitochondrial function.91
Several studies have examined the effect of amyloid beta on 
mitochondrial function, with some reporting that that exposing 
amyloid beta to mitochondria can prevent protein import into the 
mitochondria, and this would result in a deterioration of the mi‐
tochondrial membrane potential.92 Studies have shown that AD 
patients showed reduced oxidative phosphorylation, accompanied 
by reduction in complex I, III, and IV.93 In a mouse model, express‐
ing amyloid beta and tau, one study found complex I and complex 
IV were especially related to the dysregulation of oxidative phos‐
phorylation, with complex I disrupted due to tau and complex IV 
due to amyloid beta.94,95
As with PD, research into AD mitochondrial pathology deter‐
mined that AD pathology was associated with changes in mitochon‐
drial dynamics. Several papers have shown that both fusion and 
fission could be altered in AD. Although one paper has suggested 
that both fusion and fission markers are increased in AD,96 others 
report that mitochondrial fusion is decreased but mitochondrial fis‐
sion is increased in AD, which as in HD and PD causes fragmentation 
of the mitochondria.97,98 It has also been suggested that rather than 
drp1 causing mitochondrial fragmentation, the OMM receptor Fis1 
levels were increased.98 These results do suggest that any imbalance 
in the mitochondrial dynamics may have a disastrous effect on mito‐
chondrial function.
6  | FINAL REMARKS
Mitochondria have a diverse role to play in cellular function and so 
there are several different mechanisms to protect the mitochondria 
from injury and disease. When these quality control mechanisms, 
such as mitophagy or mitochondrial dynamics, fail, there can be 
devastating effects, and therefore, further research into the mecha‐
nisms of how these control systems work, such as how exactly mito‐
chondria fission occurs, will be very important.
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